2. Search Result
Search Result
Results for "

Tamoxifen

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

3

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13757A
    Tamoxifen
    Maximum Cited Publications
    83 Publications Verification

    ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
    <em>Tamoxifen</em>
  • HY-133010
    Tamoxifen N-oxide

    		Drug Metabolite Cancer
    Tamoxifen N-oxide is a Tamoxifen (HY-13757A) metabolite .
    <em>Tamoxifen</em> N-oxide
  • HY-13757AR
    Tamoxifen (Standard)
    75+ Cited Publications

    ICI 47699(Standard); (Z)-Tamoxifen(Standard); trans-Tamoxifen (Standard)

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen (Standard) is the analytical standard of Tamoxifen. This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
    <em>Tamoxifen</em> (Standard)
  • HY-13757
    Tamoxifen Citrate
    Maximum Cited Publications
    83 Publications Verification

    ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells [3].Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis [4].Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
    <em>Tamoxifen</em> Citrate
  • HY-13757AS
    Tamoxifen-​d5

    ICI 47699-​d5; (Z)-Tamoxifen-d5; trans-Tamoxifen-d5

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen-d5 is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity[1][2].
    <em>Tamoxifen</em>-​d5
  • HY-13757AS1
    Tamoxifen-d3

    ICI 47699-d3; (Z)-Tamoxifen-d3; trans-Tamoxifen-d3

    		 Estrogen Receptor/ERR Apoptosis Autophagy HSP Cancer
    Tamoxifen-d3 is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].
    <em>Tamoxifen</em>-d3
  • HY-132626S
    N-Desmethyl Tamoxifen-d5

    		Isotope-Labeled Compounds Others
    N-Desmethyl Tamoxifen-d5 is the deuterium labeled N-Desmethyl Tamoxifen[1].
    N-Desmethyl <em>Tamoxifen</em>-d5
  • HY-132477S
    (Z)-4-Hydroxy Tamoxifen-d5

    		Isotope-Labeled Compounds Others
    (Z)-4-Hydroxy Tamoxifen-d5 is the deuterium labeled (Z)-4-Hydroxy Tamoxifen[1].
    (Z)-4-Hydroxy <em>Tamoxifen</em>-d5
  • HY-118517
    α-Hydroxytamoxifen

    (E)-α-Hydroxy Tamoxifen; α-OHTAM

    		 Drug Metabolite Cancer
    α-Hydroxytamoxifen is a metabolite of tamoxifen, reacts with DNA in the absence of metabolizing enzymes, and causes formation of DNA adducts .
    α-Hydroxytamoxifen
  • HY-119437
    FLTX1
    2 Publications Verification

    		 Estrogen Receptor/ERR Cancer
    FLTX1 is a fluorescent Tamoxifen derivative that can specifically label intracellular Tamoxifen-binding sites (estrogen receptors) under permeabilized and non-permeabilized conditions. FLTX1 exhibits the potent antiestrogenic properties of Tamoxifen in breast cancer cells. FLTX1 is devoid of the estrogenic agonistic effect on the uterus .
    FLTX1
  • HY-145823
    EGFR-IN-42

    		EGFR Cancer
    EGFR-IN-42 (Compound 17b) is a potent inhibitor of EGFR with single-digit nanomolar activity. EGFR-IN-42 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-42 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-42 has superior anti-cancer activity .
    EGFR-IN-42
  • HY-145824
    EGFR-IN-43

    		EGFR Cancer
    EGFR-IN-43 (Compound 17c) is a potent inhibitor of EGFR with single-digit nanomolar activity. EGFR-IN-43 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-43 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-43 has superior anti-cancer activity .
    EGFR-IN-43
  • HY-126222
    MitoTam bromide, hydrobromide

    		Apoptosis Mitochondrial Metabolism Cancer
    MitoTam bromide, hydrobromide, a Tamoxifen derivative , is an electron transport chain (ETC) inhibitor. MitoTam bromide, hydrobromide reduces mitochondrial membrane potential in senescent cells and affects mitochondrial morphology . MitoTam bromide, hydrobromide is an effective anticancer agent, suppresses respiratory complexes (CI-respiration) and disrupts respiratory supercomplexes (SCs) formation in breast cancer cells .
    MitoTam bromide, hydrobromide
  • HY-126222A
    MitoTam iodide, hydriodide

    		Apoptosis Mitochondrial Metabolism Cancer
    MitoTam iodide, hydriodide is a Tamoxifen derivative , an electron transport chain (ETC) inhibitor, spreduces mitochondrial membrane potential in senescent cells and affects mitochondrial morphology . MitoTam iodide, hydriodide is an effective anticancer agent, suppresses respiratory complexes (CI-respiration) and disrupts respiratory supercomplexes (SCs) formation in breast cancer cells . MitoTam iodide, hydriodide causes apoptosis .
    MitoTam iodide, hydriodide
  • HY-124414S
    4'-Hydroxytamoxifen-d6 (contains up to 10% E isomer)

    		Estrogen Receptor/ERR Drug Metabolite Isotope-Labeled Compounds Others
    4'-Hydroxytamoxifen-d6 (contains up to 10% E isomer) is deuterium labeled 4'-Hydroxy Tamoxifen. 4'-Hydroxytamoxifen is a metabolite of Tamoxifen.
    4'-Hydroxytamoxifen-d6 (contains up to 10% E isomer)
  • HY-124414
    4'-Hydroxytamoxifen

    		Estrogen Receptor/ERR Drug Metabolite Cancer
    4'-Hydroxytamoxifen is a metabolite of Tamoxifen. 4'-Hydroxytamoxifen shows higher affinity for the ER than Tamoxifen. 4'-Hydroxytamoxifen induces a non-apoptotic cytotoxic effect in human endometrial adenocarcinoma cells .
    4'-Hydroxytamoxifen
  • HY-129099
    N-Desmethyltamoxifen

    		PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite Cancer
    N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .
    N-Desmethyltamoxifen
  • HY-129099A
    N-Desmethyltamoxifen hydrochloride

    		PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite Cancer
    N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .
    N-Desmethyltamoxifen hydrochloride
  • HY-18719A
    Endoxifen Z-isomer hydrochloride
    3 Publications Verification

    		 Estrogen Receptor/ERR Potassium Channel Cancer
    Endoxifen Z-isomer hydrochloride is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα).
    Endoxifen Z-isomer hydrochloride
  • HY-100910
    W-13 hydrochloride

    		CaMK Cancer
    W-13 hydrochloride is a calmodulin antagonist. W-13 hydrochloride can inhibit Tamoxifen (HY-13757A)-resistant human breast cancer cell growth .
    W-13 hydrochloride
  • HY-18719B
    Endoxifen hydrochloride

    		Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study .
    Endoxifen hydrochloride
  • HY-18719E
    Endoxifen

    		Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .
    Endoxifen
  • HY-18719
    Endoxifen (Z-isomer)
    3 Publications Verification

    		 Estrogen Receptor/ERR Potassium Channel Cancer
    Endoxifen Z-isomer is the most important Tamoxifen metabolite, inducing an anti-estrogenic effect in breast cancer cells expressing ERα. Endoxifen Z-isomer inhibits hERG. This effect is concentration-dependent, with an IC50 value of 1.6 μM.
    Endoxifen (Z-isomer)
  • HY-18719ES
    Endoxifen-d5

    		Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen-d5 is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].
    Endoxifen-d5
  • HY-110201
    Estrogen receptor modulator 1

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors .
    Estrogen receptor modulator 1
  • HY-121149
    Droloxifene
    1 Publications Verification

    3-HydroxyTamoxifen

    		 Estrogen Receptor/ERR Apoptosis Cancer
    Droloxifene, a Tamoxifen derivative, is an orally active and selective estrogen receptor modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats .
    Droloxifene
  • HY-113824
    RID-F

    Ridaifen-F

    		 Proteasome Cancer
    RID-F (Ridaifen-F), a Tamoxifen (HY-13757A) derivative, is a nonpeptidic proteasome inhibitor. RID-F inhibits human 20S proteasome activity, with IC50s of 0.64, 0.34, and 0.43 μM for CT-L, T-L, and PGPH, respectively .
    RID-F
  • HY-N0401A
    (Z)-Ligustilide
    2 Publications Verification

    		 Bacterial Infection Metabolic Disease
    (Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .
    (Z)-Ligustilide
  • HY-149295
    PROTAC ERα Degrader-4

    		PROTACs Estrogen Receptor/ERR Apoptosis Cancer
    PROTAC ERα Degrader-4 is a highly potent and selectivePROTAC ERα degrader (Ki: 5.08 μM). PROTAC ERα Degrader-4 contains OBHSAs, linker and E3 ligase ligands. PROTAC ERα Degrader-4 shows excellent cell inhibitory and ERα degradation activity against Tamoxifen-sensitive and -resistant ER + breast cancer (BC) cells and ERα-mutated BC cells. PROTAC ERα Degrader-4 can induce apoptosis and can be used for cancer research.
    PROTAC ERα Degrader-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: